Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 457

1.

Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.

Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Janicke F, Thomassen C, Look MP, Foekens JA.

Clin Breast Cancer. 2004 Dec;5(5):348-52. Review.

PMID:
15585071
[PubMed - indexed for MEDLINE]
2.

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M; German N0 Study Group.

J Natl Cancer Inst. 2001 Jun 20;93(12):913-20.

PMID:
11416112
[PubMed - indexed for MEDLINE]
Free Article
3.

Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.

Harbeck N, Kates RE, Gauger K, Willems A, Kiechle M, Magdolen V, Schmitt M.

Thromb Haemost. 2004 Mar;91(3):450-6. Review.

PMID:
14983219
[PubMed - indexed for MEDLINE]
5.

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).

Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA.

Cancer Res. 2002 Aug 15;62(16):4617-22.

PMID:
12183417
[PubMed - indexed for MEDLINE]
Free Article
6.

Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.

Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, Jänicke F, Thomssen C.

Clin Breast Cancer. 2002 Aug;3(3):196-200. Review.

PMID:
12196277
[PubMed - indexed for MEDLINE]
7.

Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.

Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CG, Lisboa BW, Lux MP, Beck T, Hasmüller S, Kiechle M, Jänicke F, Thomssen C; Chemo-N 0 Study Group.

Eur J Cancer. 2013 May;49(8):1825-35. doi: 10.1016/j.ejca.2013.01.007. Epub 2013 Mar 13.

PMID:
23490655
[PubMed - indexed for MEDLINE]
8.

Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.

Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H.

Breast Cancer Res Treat. 1993;24(3):195-208.

PMID:
8435475
[PubMed - indexed for MEDLINE]
10.

Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer.

Prechtl A, Harbeck N, Thomssen C, Meisner C, Braun M, Untch M, Wieland M, Lisboa B, Cufer T, Graeff H, Selbmann K, Schmitt M, Jänicke F.

Int J Biol Markers. 2000 Jan-Mar;15(1):73-8.

PMID:
10763145
[PubMed - indexed for MEDLINE]
11.
12.

The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.

Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Geurts-Moespot AJ, van Tienoven DT, Beex LV, Sweep FC.

Thromb Haemost. 2004 Mar;91(3):514-21.

PMID:
14983227
[PubMed - indexed for MEDLINE]
13.

Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.

Foekens JA, Look MP, Peters HA, van Putten WL, Portengen H, Klijn JG.

J Natl Cancer Inst. 1995 May 17;87(10):751-6.

PMID:
7563153
[PubMed - indexed for MEDLINE]
14.

Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer.

Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Foekens JA, Beex LV, Sweep CG.

Cancer Res. 2004 Jan 15;64(2):659-64.

PMID:
14744782
[PubMed - indexed for MEDLINE]
Free Article
15.

The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.

Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.

Cancer Res. 2000 Feb 1;60(3):636-43.

PMID:
10676647
[PubMed - indexed for MEDLINE]
Free Article
16.

High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.

Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M.

Cancer Res. 1993 Jun 1;53(11):2513-21.

PMID:
8388317
[PubMed - indexed for MEDLINE]
Free Article
17.

uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial.

Annecke K, Schmitt M, Euler U, Zerm M, Paepke D, Paepke S, von Minckwitz G, Thomssen C, Harbeck N.

Adv Clin Chem. 2008;45:31-45. Review.

PMID:
18429492
[PubMed - indexed for MEDLINE]
18.

Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.

Thomssen C, Oppelt P, Jänicke F, Ulm K, Harbeck N, Höfler H, Kuhn W, Graeff H, Schmitt M.

Anticancer Res. 1998 May-Jun;18(3C):2173-80.

PMID:
9703780
[PubMed - indexed for MEDLINE]
19.

Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.

Biermann JC, Holzscheiter L, Kotzsch M, Luther T, Kiechle-Bahat M, Sweep FC, Span PN, Schmitt M, Magdolen V.

Int J Mol Med. 2008 Feb;21(2):251-9.

PMID:
18204793
[PubMed - indexed for MEDLINE]
20.

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.

Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brünner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broët P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Jänicke F, Schmitt M, Foekens JA.

J Natl Cancer Inst. 2002 Jan 16;94(2):116-28.

PMID:
11792750
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk